The early phases of drug discovery are seeing a growing trend to return to phenotypic screening because target-based screening has had a low success rate in delivering first-in-class compounds.
High content imaging can be combined with activation state-specific antibodies in phenotypic screens to monitor drug effects on general biological processes like apoptosis, autophagy, cell cycle and migration during the early stages of the drug discovery process. These same methods can subsequently be used with more targeted antibodies to help elucidate mechanisms of action and to identify the specific pathways or individual targets affected by drug candidates.
This joint CST and TTP Labtech webinar recording will give you:
- tools for exploring protein targets in a screening environment
- protocols to assist in studying broad mechanisms of drug action and drug effects
- understanding of why rigorous validation of antibodies is critical to results
- examples of using acumen hci to perform high content, whole well analysis of combined assays at screening speeds
Dr Randy Wetzel is the cytometry director at Cell Signaling Technology. He has been at the core of CST’s expertise in assay development, flow cytometry, immunofluorescence and cell signaling for the last 11 years. Prior to that he was an instructor in neurosurgery at Massachusetts General Hospital. He received a PhD in neuroscience from Boston University.
Dr Paul Wylie is a senior applications scientist at TTP Labtech and has been developing applications for acumen for over 10 years. He has worked for Pfizer Central Research, the Institute of Cell Signaling at Nottingham University, and Knoll Pharmaceuticals. He received a PhD from Leicester University on the role of G-protein coupled receptors in kinase signaling.